The Octoparms® Vena Cava Filter, initiated for development in 2014, entered the National Medical Products Administration’s “Green Channel” for innovative medical devices in May 2020, and received approval for market launch in August 2021, filling the market gap for domestically produced umbrella-type long-term filters.

The Octoparms® Vena Cava Filter consists of a filter and a delivery system. The filter is composed of an imported nickel-titanium alloy tube, which undergoes complex and precise processes such as laser-integrated cutting and heat treatment shaping. It possesses good biocompatibility and anti-fracture performance. The balanced arms with self-centering structure, well-spaced supporting legs, and over-the-wire delivery design ensure the filter’s stable release, preventing tilting and anterior migration. It exhibits comprehensive advantages of safety, effectiveness, and long retrieval period, extending up to 3 months. The delivery system comprises a delivery sheath, introducer, and push rod. The filter is pre-loaded in the introducer and is marked with “jugular” and “femoral” indications, as well as an arrow indicating its orientation. This intuitive marking assists doctors in choosing the appropriate approach and facilitating the operation.

In clinical trials of the Octoparms® Vena Cava Filter, a 100% successful insertion rate and 100% successful retrieval rate were achieved, with no incidents of fracture, tilting, displacement, or perforation, and a zero pulmonary embolism recurrence rate within 6 months. The device has received unanimous praise from experts in its clinical application since its market launch.